- Home
- SAVA vs MPLN Comparison
SAVA vs MPLN Comparison
Compare SAVA & MPLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- MPLN
- Stock Information
- Founded
- SAVA 1998
- MPLN 1980
- Country
- SAVA United States
- MPLN United States
- Employees
- SAVA N/A
- MPLN N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- MPLN Business Services
- Sector
- SAVA Health Care
- MPLN Consumer Discretionary
- Exchange
- SAVA Nasdaq
- MPLN Nasdaq
- Market Cap
- SAVA 134.2M
- MPLN 113.4M
- IPO Year
- SAVA N/A
- MPLN N/A
- Fundamental
- Price
- SAVA $2.59
- MPLN $7.03
- Analyst Decision
- SAVA Buy
- MPLN Hold
- Analyst Count
- SAVA 3
- MPLN 2
- Target Price
- SAVA $111.50
- MPLN $25.00
- AVG Volume (30 Days)
- SAVA 12.4M
- MPLN 67.1K
- Earning Date
- SAVA 11-07-2024
- MPLN 11-05-2024
- Dividend Yield
- SAVA N/A
- MPLN N/A
- EPS Growth
- SAVA N/A
- MPLN N/A
- EPS
- SAVA N/A
- MPLN N/A
- Revenue
- SAVA N/A
- MPLN $942,614,000.00
- Revenue This Year
- SAVA N/A
- MPLN N/A
- Revenue Next Year
- SAVA N/A
- MPLN $1.17
- P/E Ratio
- SAVA N/A
- MPLN N/A
- Revenue Growth
- SAVA N/A
- MPLN N/A
- 52 Week Low
- SAVA $2.55
- MPLN $4.80
- 52 Week High
- SAVA $42.20
- MPLN $69.20
- Technical
- Relative Strength Index (RSI)
- SAVA 23.06
- MPLN 45.06
- Support Level
- SAVA $2.78
- MPLN $6.80
- Resistance Level
- SAVA $3.28
- MPLN $7.89
- Average True Range (ATR)
- SAVA 0.24
- MPLN 0.67
- MACD
- SAVA 0.40
- MPLN 0.08
- Stochastic Oscillator
- SAVA 4.73
- MPLN 39.53
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About MPLN MultiPlan Corporation
MultiPlan Corp is a provider of data analytics and technology-enabled solutions designed to bring affordability, efficiency, and fairness to the U.S. healthcare industry. The company interprets clients' needs and customizes solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry.